A5028484936- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Cancer Immunotherapy and Biomarkers
- Hematopoietic Stem Cell Transplantation
- Viral Infectious Diseases and Gene Expression in Insects
- Virus-based gene therapy research
- Nanowire Synthesis and Applications
- Biosimilars and Bioanalytical Methods
- Cytomegalovirus and herpesvirus research
- Systemic Lupus Erythematosus Research
- Erythropoietin and Anemia Treatment
- Chemokine receptors and signaling
- Biosensors and Analytical Detection
- Biomedical Ethics and Regulation
- Ovarian cancer diagnosis and treatment
- Xenotransplantation and immune response
- Reproductive System and Pregnancy
- Erythrocyte Function and Pathophysiology
- Biomedical and Engineering Education
- Renal and related cancers
- RNA Interference and Gene Delivery
- Contact Dermatitis and Allergies
Yamaguchi University
2012-2024
SDS Biotech (Japan)
2023
University of Maryland, Baltimore
2009-2014
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
2010
Kyushu University
2005-2008
Okayama University
2004-2007
Abstract Purpose: To develop an adaptable gene-based vector that will confer immune cell specificity to various cancer types. Experimental Design: Human and mouse T cells were genetically engineered express a chimeric antigen receptor (CAR) binds fluorescein isothiocyanate (FITC) molecule, termed anti-FITC CAR cells. Various antibodies (Ab) currently in clinical use including cetuximab (Ctx), trastuzumab (Her2), rituximab (Rtx) conjugated with FITC tested for their ability bind tumor cells,...
Abstract Chimeric antigen receptor‐engineered T ( CAR ‐T)‐cell therapy holds significant promise for the treatment of hematological malignancies, especially B‐cell leukemia and lymphoma. However, its efficacy against non‐hematological malignancies has been limited as a result several biological problems characteristic tumor microenvironment solid tumors. One main hurdles is heterogeneous nature tumor‐associated antigens TAA ) expressed in Another hurdle inefficient activation persistence ‐T...
<p>Supplementary Figure 3. Immunophenotypic analyses of 7×19 CAR-T.</p>
<p>Supplementary Figure 1. Generation and characterization of anti-EGFRvⅢ CAR-T cells expressing IL-7 CCL19.</p>
<p>Supplementary Figure 4. Generation and characterization of anti-HER2 CAR-T cells expressing IL-7 CCL19.</p>
<p>Supplementary Figure 2. Therapeutic effects of lower number 7×19 CAR-T in pre-established solid tumor model human glioblastoma.</p>
Abstract Introduction Soluble immune aggregates bearing intact Fc fragments are effective treatment for a variety of autoimmune disorders in mice. The better to understand the mechanisms by which Fc-bearing complexes suppress autoimmunity, and develop platform clinical translation, we created series fully recombinant forms polyvalent IgG2a Fc, termed stradomers, tested their efficacy therapeutic model collagen-induced arthritis (CIA) preventive models both idiopathic thrombocytopenic purpura...
Abstract Chimeric antigen receptor (CAR)‐T cell therapy has shown salient efficacy in cancer immunotherapy, particularly the treatment of B malignancies. However, CAR‐T for solid tumors remains inadequate. In this study, we displayed that c‐met is an appropriate therapeutic target papillary renal carcinoma (PRCC) using clinical samples, developed anti‐human cells, and investigated anti‐tumor cells orthotopic mouse model as pre‐clinical research. Administration anti‐c‐met induced marked...
Abstract Background While chimeric antigen receptor (CAR)‐T cell therapy has demonstrated excellent efficacy in hematopoietic malignancies, its clinical application solid cancers yet to be achieved. One of the reasons for such hurdle is a lack suitable CAR targets cancers. Methods GM2 one gangliosides, group glycosphingolipids with sialic acid glycan, and overexpressed various types In this study, by using interleukin (IL)‐7 chemokine (C‐C motif) ligand 19 (CCL19)‐producing human CAR‐T...
Therapeutic cancer vaccines are designed to treat by boosting the endogenous immune system fight against cancer. In development of clinically effective vaccines, one most practical objectives is identify adjuvants that capable optimizing vaccine effects. this study, we explored potential polyinosinic–polycytidylic acid (poly(I:C)) and LAG ‐3‐Ig (soluble recombinant protein lymphocyte activation gene‐3 [ ‐3] extracellular domain fused with human IgG Fc region) as for P1A tumor antigen peptide...
FTY720 is a novel immunosuppressant that improves the outcomes after solid organ and bone marrow transplantation (BMT) due to sequestration of T cells into LN. We tested hypothesis donor in LN by would enhance their interaction with host APC, thus causing greater degree activation-induced apoptosis alloreactive cells, thereby resulting reduction graft-vs.-host disease (GVHD). The short-term administration improved recipient survival allogeneic BMT. treatment facilitated rapid contraction...
Omega (ω)-3 long-chain polyunsaturated fatty acids (LCPUFAs) inhibit the production of inflammatory mediators and thereby contribute to regulation inflammation. Experimental autoimmune uveitis (EAU) is a well-established animal model retinal To investigate potential effects dietary intake ω-3 LCPUFAs on uveitis, we examined anti-inflammatory properties these molecules in comparison with ω-6 mouse EAU model. C57BL/6 mice were fed diet containing or for 2 weeks before as well after induction...
Interactions between NK and dendritic cells (DC) affect maturation function of both cell populations, including killing DC (editing) that is important for controlling the quality immune responses. We also know antigen-stimulated Vγ2Vδ2 T costimulate via 4-1BB to enhance tumor lines but we do not what regulates expression or whether other effector functions killing, might be influenced by NK:γδ cross talk. Here show γδ through ICOS:ICOSL this signal increases autologous DC. Effects...
Abstract Although adoptive transfer of T cells genetically engineered to express chimeric antigen receptor (CAR) or T-cell (TCR) has been actively developed and applied into clinic recently, further improvement these modalities is highly demanded, especially in terms its efficacy. Because we previously revealed the profound enhancement antitumor effects CAR by concomitant expression IL7 CCL19, this study explored a potential IL7/CCL19 production technology augment TCR cells....
Abstract Herpesvirus entry mediator (HVEM), a member of the TNFR superfamily, serves as unique molecular switch to mediate both stimulatory and inhibitory cosignals, depending on its functions receptor or ligand interacting with multiple binding partners. In this study, we explored cosignaling HVEM in experimental autoimmune uveitis (EAU), mouse model resembling human conditions such ocular sarcoidosis Behcet disease. Our studies revealed that EAU severity significantly decreased...
Cancer immunotherapy using immune checkpoint inhibitors and its combination with other anticancer therapies has emerged as a new standard of care because the encouraging therapeutic effects in various solid cancers. Nonetheless, glioblastoma pancreatic cancer remain resistant to represent intractable cancers poorest prognosis. We investigated next-generation chimeric antigen receptor (CAR) T cells producing IL7 chemokine (C-C motif) ligand 19 (CCL19; referred 7 × CAR-T) these Cytotoxic...
Summary Leucocyte‐associated immunoglobulin‐like receptor‐1 (LAIR‐1) is a membrane receptor of the immunoglobulin (Ig) superfamily that expressed on most types haematopoietic cells, and delivers inhibitory signals through interacting with collagens. In order to elucidate immunological functions LAIR‐1 in vivo , we established transgenic mice expressing chimeric protein composed extracellular domain fused an Ig tag (LAIR‐1–Ig), which acts as decoy by competing endogenous LAIR‐1. The showed...